Sonnet Stockholders Approve Merger With Hyperliquid Strategies Deal

Sonnet BioTherapeutics Holdings, Inc. announced stockholder approval of its proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC. The decision followed a special meeting, and the final voting results will be filed with the U.S. Securities and Exchange Commission.

Source: coincu.com

Related symbols: HYPEUSD